TABLE 3.
Cytokine production in PBMC cultures from CE patients divided into two groups according to clinical outcome of disease
| Stimulus | Cytokine | Patients with:
|
|||
|---|---|---|---|---|---|
| Cured or stable disease (n = 21)
|
Progressive disease (n = 19)
|
||||
| No. testing positive (%) | Mean (range) concn (pg/ml)a | No. testing positive (%) | Mean (range) concn (pg/ml)a | ||
| None | IL-4 | 21 (100) | 0.4 (0.02–0.9) | 17 (89) | 0.2 (0–0.8) |
| IL-13 | 2 (5) | 0.003 (0–27) | 2 (14) | 0.003 (0–164) | |
| IFN-γ | 15 (71) | 0.4 (0–58) | 11 (58) | 0.1 (0–31) | |
| IL-12 | 10 (48) | 0.02 (0–4.5) | 9 (47) | 0.01 (0–0.9) | |
| AgB | IL-4 | 21 (100) | 1.1 (0.35–4.9) | 19 (100) | 0.9 (0.2–3.1) |
| IL-13 | 18 (86) | 59.1 (0–2,415) | 17 (89) | 33.0 (0–1,144) | |
| IFN-γ | 17 (81) | 21.2 (0–285) | 18 (95) | 3.0 (0–523) | |
| IL-12 | 12 (57) | 0.048* (0–3.8) | 8 (42) | 0.004* (0–0.5) | |
| SHF | IL-4 | 21 (100) | 1.3 (0.4–5.0) | 19 (100) | 1.2 (0.2–3.9) |
| IL-13 | 20 (95) | 185.3 (0–2,313) | 18 (95) | 177.2 (0–2,193) | |
| IFN-γ | 21 (100) | 266.3 (9–1,000) | 19 (100) | 200.0 (32–1,162) | |
| IL-12 | 15 (71) | 0.1 (0–2.5) | 11 (58) | 0.03 (0–2.5) | |
a
Statistically significant difference: *, P = 3 × 10−2.